PDF(Pubmed)
Abstract：
UNASSIGNED: In October 2013, Burkina Faso introduced 13-valent pneumococcal conjugate vaccine (PCV13) into the routine childhood immunization program using 3 primary doses with no booster. Previous pneumococcal carriage studies showed reductions in vaccine-type (VT) carriage in children aged <5 years but not in older age groups.
UNASSIGNED: We conducted a cross-sectional, age-stratified pneumococcal carriage study among healthy persons aged ≥1 month in Bobo-Dioulasso in March 2020. Pneumococci isolated by culture from nasopharyngeal swabs (all participants) and oropharyngeal swabs (participants aged ≥5 years) were serotyped by polymerase chain reaction; a subset was serotyped by Quellung. Using data from a study with the same design from March 2017, we examined changes in pneumococcal carriage by age group.
UNASSIGNED: Among 1005 (2017) and 1002 (2020) enrolled participants, VT carriage decreased (21.6% to 15.9%; adjusted prevalence ratio [aPR], 0.76 [95% confidence interval {CI}, .63-.92]). By age group, decline in VT carriage was significant among children aged 5-14 years (28.9% to 16.3%; aPR, 0.57 [95% CI, .39-.84]) but not among children aged <5 years (22.4% to 19.1%; aPR, 0.87 [95% CI, .70-1.09]) or adults aged ≥15 years (12.0% to 5.5%; aPR, 0.52 [95% CI, .26-1.05]).
UNASSIGNED: Between 3 and 6 years after PCV13 introduction, significant declines in VT carriage were observed in older children, possibly reflecting indirect effects of PCV13 use. VT carriage in children aged <5 years remained stable with almost 1 in 5 carrying VT pneumococci, suggesting limitations to a PCV schedule without a booster dose.
UNASSIGNED: We conducted a cross-sectional, age-stratified pneumococcal carriage study among healthy persons aged ≥1 month in Bobo-Dioulasso in March 2020. Pneumococci isolated by culture from nasopharyngeal swabs (all participants) and oropharyngeal swabs (participants aged ≥5 years) were serotyped by polymerase chain reaction; a subset was serotyped by Quellung. Using data from a study with the same design from March 2017, we examined changes in pneumococcal carriage by age group.
UNASSIGNED: Among 1005 (2017) and 1002 (2020) enrolled participants, VT carriage decreased (21.6% to 15.9%; adjusted prevalence ratio [aPR], 0.76 [95% confidence interval {CI}, .63-.92]). By age group, decline in VT carriage was significant among children aged 5-14 years (28.9% to 16.3%; aPR, 0.57 [95% CI, .39-.84]) but not among children aged <5 years (22.4% to 19.1%; aPR, 0.87 [95% CI, .70-1.09]) or adults aged ≥15 years (12.0% to 5.5%; aPR, 0.52 [95% CI, .26-1.05]).
UNASSIGNED: Between 3 and 6 years after PCV13 introduction, significant declines in VT carriage were observed in older children, possibly reflecting indirect effects of PCV13 use. VT carriage in children aged <5 years remained stable with almost 1 in 5 carrying VT pneumococci, suggesting limitations to a PCV schedule without a booster dose.
摘要：
■2013年10月，布基纳法索在常规儿童免疫计划中引入了13价肺炎球菌结合疫苗（PCV13），使用3次主要剂量，无需加强。先前的肺炎球菌携带研究显示，5岁以下儿童的疫苗型（VT）携带减少，但年龄较大的儿童没有。
■我们进行了横截面，2020年3月在Bobo-Dioulasso对年龄≥1个月的健康人进行的年龄分层肺炎球菌携带研究。从鼻咽拭子（所有参与者）和口咽拭子（年龄≥5岁的参与者）中通过培养分离的肺炎球菌通过聚合酶链反应进行血清分型;Quellung对一个子集进行血清分型。使用来自2017年3月相同设计的研究数据，我们检查了按年龄组划分的肺炎球菌携带变化。
■在1005（2017年）和1002（2020年）注册参与者中，室性心动过速携带下降(21.6%至15.9%；调整后的患病率[aPR]，0.76[95%置信区间{CI}，.63-.92]）。按年龄组,室性心动过速下降在5-14岁儿童中显著(28.9%至16.3%；aPR，0.57[95%CI，.39-.84])，但在5岁以下的儿童中没有(22.4%至19.1%；aPR，0.87[95%CI，.70-1.09])或≥15岁的成年人(12.0%至5.5%；aPR，0.52[95%CI，.26-1.05]）。
■在PCV13推出后的3到6年之间，在年龄较大的儿童中观察到VT携带显着下降，可能反映了PCV13使用的间接影响。<5岁儿童的VT携带保持稳定，几乎每5人中就有1人携带VT肺炎球菌，建议在没有加强剂量的情况下限制PCV时间表。
■我们进行了横截面，2020年3月在Bobo-Dioulasso对年龄≥1个月的健康人进行的年龄分层肺炎球菌携带研究。从鼻咽拭子（所有参与者）和口咽拭子（年龄≥5岁的参与者）中通过培养分离的肺炎球菌通过聚合酶链反应进行血清分型;Quellung对一个子集进行血清分型。使用来自2017年3月相同设计的研究数据，我们检查了按年龄组划分的肺炎球菌携带变化。
■在1005（2017年）和1002（2020年）注册参与者中，室性心动过速携带下降(21.6%至15.9%；调整后的患病率[aPR]，0.76[95%置信区间{CI}，.63-.92]）。按年龄组,室性心动过速下降在5-14岁儿童中显著(28.9%至16.3%；aPR，0.57[95%CI，.39-.84])，但在5岁以下的儿童中没有(22.4%至19.1%；aPR，0.87[95%CI，.70-1.09])或≥15岁的成年人(12.0%至5.5%；aPR，0.52[95%CI，.26-1.05]）。
■在PCV13推出后的3到6年之间，在年龄较大的儿童中观察到VT携带显着下降，可能反映了PCV13使用的间接影响。<5岁儿童的VT携带保持稳定，几乎每5人中就有1人携带VT肺炎球菌，建议在没有加强剂量的情况下限制PCV时间表。
